Subscribe Now Subscribe Today
Research Article
 

Solid Lipid Nanoparticles Preparation and Characterization



N. AL-Haj and A. Rasedee
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail
ABSTRACT

The presents study aimed to prepare and characterize Solid Lipid Nanoparticles (SLNs) from palm oil materials. Hydrogenated palm oil and lecithin incorporated with surfactant were mixed and formed by High Pressure Homogenization (HPH) at elevated temperature. Appropriate analytical methods are needed for the characterization of SLN. The use of several analytical techniques is a necessity such as particle size which determined using Photon Correlation Spectroscopy (PCS). The change of particle charge was studied by Zeta Potential (ZP) measurements, while the melting and recrystallization behavior characterized by Differential Scanning Calorimetry (DSC). Data showed physical stability of the formulation. In conclusion, the SLN presented here are well suited for several applications including drug delivery.

Services
Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

N. AL-Haj and A. Rasedee, 2009. Solid Lipid Nanoparticles Preparation and Characterization. International Journal of Pharmacology, 5: 90-93.

DOI: 10.3923/ijp.2009.90.93

URL: https://scialert.net/abstract/?doi=ijp.2009.90.93
 

INTRODUCTION

Solid Lipid Nanoparticles (SLN) (Mehnert and Mader, 2001; Muller et al., 2000) have been introduced to the literature as a carrier system for poorly water-soluble pharmaceutical drugs (Ugazio et al., 2002; Westesen et al., 1997) and cosmetic active ingredients (Jenning et al., 2000a; Lippacher et al., 2002, 2004; Wissing and Muller, 2003a, b). Advantages of SLN include a potentially wide application spectrum (dermal, oral, intravenous), the use of biodegradable physiological lipids or lipidic stabilisers which are Generally Recognized as Save (GRAS) or have a regulatory accepted status, the production without organic solvents and the possibility of scaling up to industrial production level (Wan et al., 2008; Gohla and Dingler, 2001; Liedtke et al., 2000). The predominant production technique till recently was the High Pressure Homogenization (HPH) method (Lander et al., 2000; Siekmann and Westesen, 1994). To avoid the organic solvents and the large amount of surfactants and other additions introduced, this method have some clear advantages for production of SLNs (AL-Haj et al., 2008; Kim et al., 2005).

MATERIALS AND METHODS

Lipid Matrices (LM) preparation: present study was conducted in the Universiti Putra Malaysia Novmber, 2007. Hydrogenated palm oil Softisan 154, solid lipid triglyceride mixture, was donated from Condea (Witten, Germany). Phospholipon 90 H is a completely hydrogenated lecithin from Phospholipid (Cologne, Germany). The lipid matrix composition was varied by incorporation of 0-50 % Phospholipon 90 H (w/w) within Softisan 154. Oleyl alcohol long-chain fatty alcohols and thimerosal used as a preservative were purchased from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). The mixtures were stirred with a teflon coated magnet at 80 °C until a transparent yellow solution was obtained. The solution was stirred at room temperature until solidification. Bidistilled water was used for all preparations and all chemicals were of pharmacopeial or reagent grade.

Solid Lipid Nanoparticles (SLN) preparation: Basic formulation of SLN contained 10% of Hydrogenated palm oil Softisan 154 and hydrogenated lecithin (lipid matrix), 1% Oleyl alcohol, 0.005% thimerosal and 89% bidistilled water (all w/w). All components were weighted into sealed containers and heated to 80 °C. Thereafter a preemulsion was produced using an Ultra Turrax (Ika/Staufen, Germany) at 10,000 rpm for 10 min. The hot preemulsions were homogenised at a pressure of 1000 bar and a temperature of about 70 °C with an EmulsiFlexw-C5 (Avestin, Canada) high pressure homogeniser for 10 cycles. Subsequently, the dispersions were allowed to recrystallise at room temperature (Liedtke et al., 2000).

Transmission Electron Microscopy (TEM): The morphology of the SLN was examined by TEM (Hitachi, Japan). The samples were stained with 2% (w/v) phosphotungstic acid for 30sec and placed on copper grids with films for viewing.

Particle size measurement: The average diameter and Polydispersity Index (PI) of SLN were determined by Photon Correlation Spectroscopy (PCS) using a Zetasizer 3 (Malvern Instruments, Malvern, UK) at a fixed angle of 90 and at 25 °C. The aqueous SLN dispersions were diluted with distilled water before analysis. Each value is the average of 3 measurements.

Zeta potential measurement: The particle charge was quantified as Zeta Potential (ZP) using a Zetasizer 4 at 25 °C. Before measuring, each sample had to be diluted with demineralized particle free water to an adequate intensity. Each measurement was performed at least in triplicate. The pH values of the samples were always between 6.2 ± 0.9.

Differential scanning calorimetry: Differential Scanning Calorimetry (DSC) was performed with a Mettler DSC 822e (Mettler Toledo, Greifensee, Switzerland). Samples containing ~10 mg nanoparticle dispersions (identical to 1-2 mg of solid lipid) were weighed accurately into standard aluminum pans using an empty pan as a reference. DSC scans were recorded at a heating and cooling rate of 5 °C min-1. The samples were heated from 25 to 85 °C and cooled from 85 to 20 °C under liquid nitrogen. Enthalpies were calculated using the Mettler Star software.

RESULTS AND DISCUSSION

Transmission electron microscopy: Solid Lipid Nanoparticles (SLN) are the new generation of nanoparticulate active-substance vehicles and are attracting major attention as novel colloidal drug carriers for topical use (Wan et al., 2008). SLN are commonly produced by the hot homogenisation technique (AL-Haj et al., 2008). Alternatively a cold homogenisation process can be used to incorporate temperature sensitive drugs or to increase drug encapsulation. Nanoparticles were produced by either hot or cold homogenisation technique as described by Wissing and Muller (2002). Nanoparticles emulsified by a mixture of Lipid matrix and surfactant were produced at 1000 bar using the hot homogenisation technique. So, in practice, samples were taken after 10 homogenisation cycles lead to reproducible and satisfying results. The number of homogenisation cycles necessary to decrease the polydispersity and to get a small particle population was slightly different. The electron microscopy micrographs of SLN were shown in Fig. 1. The shape of SLN was spherical and particle size was approximately from 25 to 150nm.

Average diameter and zeta potential: An adequate characterization of the solid lipid particles is a necessity for the control of the quality of the product. PCS the most powerful techniques for routine measurements of particle size. The average diameter of SLN measured by PCS Zetasizer 4 was 108.48 nm (n = 5) was showed in Table 1.

The measurement of the zeta potential allows predictions about the storage stability of colloidal dispersion. In general, particle aggregation is less likely to occur for charged particles (high zeta potential) due to electric repulsion (Müller et al., 2000). The zeta potential distribution of SLN was showed in Table 1. The mean zeta potential was -15.4mV (n = 5). Therefore, this method had gained a relative good stability and dispersion quality.

Image for - Solid Lipid Nanoparticles Preparation and Characterization
Fig. 1: TEM micrograph of SLN, bar = 200nm

Image for - Solid Lipid Nanoparticles Preparation and Characterization
Fig. 2: Differential scanning calorimetry scans of SLN

Table 1: Particle size and zeta potential with polydispersity index (PI) of SLN
Image for - Solid Lipid Nanoparticles Preparation and Characterization

Using DSC analysis, cooling scans are the most sensitive method to detect polymorphic forms. Freitas and Muller (1999) and Mühlen et al. (1998) used this method to investigate the different crystallization of SLN. The cooling curves obtained 1 day after production showed that the formulation recrystallized in different polymorphic forms. SLN cooling curve shows a main peak at 57.8 °C which can be attributed to the beta modification (Fig. 2). But if the SLN cooling curve of the peak higher than 62 °C suggested the presence of alpha modifications (Mühlen et al., 1998).

The melting points of colloidal systems were distinctly decreased by about 10-15 °C. According to Wan et al. (2008) the melting point decrease of colloidal systems can be assigned to the colloidal dimensions of the particles in particular to their large surface to volume ratio and not to recrystallisation of the lipid matrices in a metastable polymorph possessing a lower melting point. Nevertheless, the melting point reduction of the different formulations has no apparent relation to the particle size data not show.

CONCLUSION

Solid Lipid Nanoparticles (SLN) as Drug carriers have unique characteristics that can enhance performance in a variety of dosage forms. We will focus on providing services for production, formulation and characterization of nanoparticles with clear advantages and disadvantages to other colloidal carriers.

ACKNOWLEDGMENTS

We would like to thank R. Abbasalipour for her kind help and Condea and Nattermann Phospholipid for kind support with materials.

REFERENCES

  1. Lippacher, A., R.H. Muller and K. Mader, 2002. Semisolid SLN™ dispersions for topical application: Influence of formulation and production parameters on viscoelastic properties. Eur. J. Pharm. Biopharm., 53: 155-160.
    CrossRef  |  


  2. Siekmann, B. and K. Westesen, 1994. Melt-homogenized solid lipid nanoparticles stabilized by the nontonic surfactant tyloxapol 1. Preparation and particle size determination. Pharm. Pharmacol. Lett., 3: 194-197.


  3. Kim, B.D., K. Na and H.K. Choi, 2005. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur. J. Pharm. Sci., 24: 199-205.
    CrossRef  |  


  4. Freitas, C. and R.H. Muller, 1999. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm., 47: 125-132.
    CrossRef  |  


  5. Ugazio, E., R. Cavalli and M.R. Gasco, 2002. Incorporation of cyclosporin A in Solid Lipid Nanoparticles (SLN). Int. J. Pharm., 241: 341-344.
    CrossRef  |  


  6. Wan, F., J. You, Y. Sun, Z. Xing-Guo and C. Fu-De, 2008. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): Preparation and evaluation in vitro, I. Int. J. Pharm., 359: 104-110.
    CrossRef  |  


  7. Muller,R.H., K. Mader and S. Gohla, 2000. Solid Lipid Nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm., 50: 161-177.
    CrossRef  |  


  8. Westesen, K., H. Bunjes and M.H.J. Koch, 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J. Control Release, 48: 223-236.
    CrossRef  |  Direct Link  |  


  9. Lippacher, R.H. Muller and K. Mader, 2004. Liquid and semisolid SLN™ dispersions for topical application: Rheological characterization. Eur. J. Pharm. Biopharm., 58: 561-567.
    CrossRef  |  


  10. AL-Haj, N., R. Abbasalipour and A. Rasedee, 2008. A solid lipid nanoparticles preparation, characterization and production from palm oil. Proceedings of the Asian Scientific Conference in Pharmaceutical Technology, June 1-3, 2008, Singapore, pp: 37-37


  11. Lander, R., W. Manger, M. Scouloudis, A. Ku, O. Davis and A. Lee, 2000. Gaulin homogenization: A mechanistic study. Biotechnol. Prog., 16: 80-85.
    CrossRef  |  


  12. Wissing, S.A. and R.H. Muller, 2003. Cosmetic applications for solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm., 56: 67-72.
    CrossRef  |  


  13. Wissing, S.A. and R.H. Müller, 2002. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J. Control Release, 81: 225-233.
    CrossRef  |  


  14. Wissing, S.A. and R.H. Muller, 2003. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity in vivo study. Int. J. Pharm., 254: 65-68.
    CrossRef  |  


  15. Gohla, S.H. and A. Dingler, 2001. Scaling up feasibility of the production of solid lipid nanoparticles (SLN„). Die Pharmazie, 56: 61-63.
    PubMed  |  


  16. Liedtke, S., S. Wissing, R.H. Muller and K. Mader, 2000. Influence of high pressure homogenisation equipment on nanodispersions characteristics. Int. J. Pharm., 196: 183-185.
    CrossRef  |  Direct Link  |  


  17. Jenning, V., A.F. Thunemann and S.H. Gohla, 2000. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm., 199: 167-177.
    CrossRef  |  


  18. Mehnert, W. and K. Mader, 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev., 47: 165-196.
    CrossRef  |  


  19. Muhlen, A.Z., C. Schwarz and W. Mehnert, 1998. Solid Lipid Nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm., 45: 149-155.
    CrossRef  |  PubMed  |  Direct Link  |  


©  2022 Science Alert. All Rights Reserved